Baha Eddin El Khatib, MD
Retina Specialist · Canton, OHNPI 1417481946
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $10,340 of the $14,709 with a category attached, or 70.3%. Regeneron accounts for 78.8% of it on its own, with 13 other manufacturers making up the rest. 2025 is the largest year on record at $12,872, more than ten times the $401 reported in 2021.
Across 102 payments — averaging $144.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Regeneron$12K
- Regeneron Healthcare Solutions, Inc.$610
- Alimera Sciences, Inc.$503
- Apellis Pharmaceuticals, Inc.$479
- Alcon$401
- Astellas Pharma US Inc$239
- plus $888 from 8 others
What the payments were for
- Consulting fees$10,34070%
- Travel & lodging$9607%
- Food & beverage$3,40923%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Regeneron | 13 | $11,589 |
| Regeneron Healthcare Solutions, Inc. | 36 | $610 |
| Alimera Sciences, Inc. | 4 | $503 |
| Apellis Pharmaceuticals, Inc. | 13 | $479 |
| Alcon | 1 | $401 |
| Astellas Pharma US Inc | 7 | $239 |
| Genentech USA, Inc. | 10 | $204 |
| Ocular Therapeutix, Inc. | 1 | $152 |
| AbbVie | 5 | $147 |
| Astellas Pharma Global Development | 1 | $143 |
| Harrow Eye, LLC | 5 | $125 |
| ANI Pharmaceuticals, Inc. | 3 | $61 |
| Rayner Intraocular Lenses Limited | 2 | $38 |
| Bausch & Lomb Americas Inc. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$14,709 in reported general payments places this provider in the 75th percentile of 69 retina specialist providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 255 | $9,758 |
| Ketorolac Tromethamine | 110 | $4,788 |
| Ofloxacin | 140 | $1,730 |
| Brimonidine Tartrate | 23 | $1,339 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 125 | $1,307 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 69 | $861 |
| Atropine Sulfate | 12 | $453 |
| Timolol Maleate | 18 | $294 |
| Latanoprost | 12 | $96 |
Paid to pharmacies, not to this prescriber.
Other retina specialist in Canton
- Arnold NothnagelCanton$5K
- Sophia PachydakiCanton$4K
- Mark GersmanCanton$3K
- Robert WenzCanton$2K
- Stephen ContiCanton$1K
- Richard WyszynskiCanton$920
- Deepam RusiaCanton$221
- Joseph ConeyBeachwood$980K
- Sumit SharmaCleveland$428K
- Aleksandra RachitskayaCleveland$303K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.